11 August 2022
RADNOR, Pa.--(BUSINESS WIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2022.
“We had an exciting second quarter as we continued to prepare for the commercial launch of ZTALMY and progressed our Phase 3 TrustTSC and RAISE trials, including new U.S. site activations and the implementation of important changes to the RAISE protocol to further support recruitment and enrollment,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “In addition to driving adoption of ZTALMY, we look forward to advancing our late-stage clinical trials and positioning Marinus as a leader in epilepsy drug development. We are confident in our ability to identify a second generation program well-suited for development in Lennox-Gastaut syndrome with pharmacokinetic characteristics that allow for greater individualization of dosing.”
Ganaxolone development in the RAISE trial is being funded in part by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, under contract number 75A50120C00159.
Selected Financial Data (in thousands, except share and per share amounts) |
||||||||
June 30, |
December 31, |
|||||||
2022 |
2021 |
|||||||
ASSETS |
||||||||
Cash and cash equivalents |
$ |
92,326 |
$ |
122,927 |
||||
Other assets |
17,051 |
13,913 |
||||||
Total assets |
$ |
109,377 |
$ |
136,840 |
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities |
$ |
23,110 |
$ |
40,566 |
||||
Long Term Debt, Net |
70,350 |
40,809 |
||||||
Other long-term liabilities |
11,114 |
1,979 |
||||||
Total liabilities |
104,574 |
83,354 |
||||||
Total stockholders’ equity |
4,803 |
53,486 |
||||||
Total liabilities and stockholders’ equity |
$ |
109,377 |
$ |
136,840 |
Three Months Ended |
Six Months Ended June 30, |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
Revenue: |
||||||||||||||||
Federal contract revenue |
$ |
1,790 |
$ |
1,905 |
$ |
3,303 |
$ |
3,711 |
||||||||
Collaboration revenue |
— |
— |
12,673 |
— |
||||||||||||
Total revenue |
1,790 |
1,905 |
15,976 |
3,711 |
||||||||||||
Expenses: |
||||||||||||||||
Research and development |
21,495 |
18,562 |
39,486 |
37,153 |
||||||||||||
General and administrative |
17,061 |
6,828 |
28,798 |
17,204 |
||||||||||||
Cost of IP license fee |
— |
— |
1,169 |
— |
||||||||||||
Total expenses: |
38,556 |
25,390 |
69,453 |
54,357 |
||||||||||||
Loss from operations |
(36,766 |
) |
(23,485 |
) |
(53,477 |
) |
(50,646 |
) |
||||||||
Interest income |
84 |
16 |
96 |
40 |
||||||||||||
Interest expense |
(2,656 |
) |
(351 |
) |
(4,348 |
) |
(351 |
) |
||||||||
Other expense, net |
(95 |
) |
(3 |
) |
(1,065 |
) |
(7 |
) |
||||||||
Net loss and comprehensive loss |
$ |
(39,433 |
) |
$ |
(23,823 |
) |
$ |
(58,794 |
) |
$ |
(50,964 |
) |
||||
Net loss applicable to common shareholders |
$ |
(39,433 |
) |
$ |
(23,823 |
) |
$ |
(58,794 |
) |
$ |
(50,964 |
) |
||||
Per share information: |
||||||||||||||||
Net loss per share of common stock—basic and diluted |
$ |
(1.06 |
) |
$ |
(0.65 |
) |
$ |
(1.59 |
) |
$ |
(1.39 |
) |
||||
Basic and diluted weighted average shares outstanding |
37,155,917 |
36,659,615 |
37,023,976 |
36,629,823 |
Conference Call Information
Thursday, August 11, at 8:30 a.m. ET
Domestic: (888) 550-5280
International: (646) 960-0813
Webcast Link: https://events.q4inc.com/attendee/716641338
Conference ID: 2696394
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our commercialization and marketing plans for ZTALMY; the potential benefits ZTALMY will provide for physicians and patients; our expectations regarding the ZTALMY One program; statements regarding our expected clinical development plans, enrollment in our clinical trials, regulatory communications and submissions for ganaxolone, and the timing thereof; statements regarding the completion of the contemplated sale of the PRV (including the satisfaction of the conditions thereto) and the expected timing thereof; our plans with respect to the use of the PRV sale proceeds; our expected cash runway following the completion of the contemplated sale of the PRV; our expectations regarding BARDA funding; our expectations and beliefs regarding the FDA and EMA with respect to our product candidates; our expectations regarding the development of new formulations and prodrug candidates; our expectation regarding the impact of the COVID-19 pandemic on our business and clinical development plans; our financial projections; the potential safety and efficacy of ganaxolone, as well as its therapeutic potential in a number of indications; and other statements regarding the company's future operations, financial performance, financial position, prospects, objectives and other future event.
Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, unexpected results or delays in the commercial launch of ZTALMY, including any potential delays caused by the current COVID-19 global pandemic; unexpected market acceptance, payor coverage or future prescriptions and revenue generated by ZTALMY; unexpected actions by the FDA or other regulatory agencies with respect to our products; competitive conditions and unexpected adverse events or patient outcomes from being treated with ZTALMY, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; risks and uncertainties relating to the antitrust review process and the ability of the parties to consummate the PRV sale transaction; the risk that the closing conditions in the PRV purchase agreement are not met; the varying interpretation of clinical data; our ability to comply with the FDA’s requirement for additional post-marketing studies in the required time frames; the timing of regulatory filings for our other product candidates; the potential that regulatory authorities, including the FDA and EMA, may not grant or may delay approval for our product candidates; early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of the FDA or EMA may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; our ability to develop new formulations of ganaxolone or prodrugs; our ability to obtain, maintain, protect and defend intellectual property for our product candidates; the potential negative impact of third party patents on our or our collaborators’ ability to commercialize ganaxolone; delays, interruptions or failures in the manufacture and supply of our product candidate; the size and growth potential of the markets for the company’s product candidates, and the company’s ability to service those markets; the company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the company’s ability to obtain additional funding to support its clinical development and commercial programs; the potential for Orion to breach the collaboration or terminate the agreement in accordance with its terms; the risk that drug product quality requirements may not support continued clinical investigation of our product candidates and result in delays or termination of such clinical studies and product approvals; the effect of the COVID-19 pandemic on our business, the medical community, regulators and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. This list is not exhaustive and these and other risks are described in our periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
2024 drug approvals: Small companies loom large with several key FDA nods
13 January 2025
Special Regulations for Foreign-Packaged Medicines Extended Until the End of 2025
13 January 2025
Russia Begins Production of Terbium-161 Isotope for Cancer Therapy
10 January 2025
FMBA has begun clinical trials of a vaccine against five serotypes of meningococcus
10 January 2025